Wie hoch ist der Preis für National Graphite Corp. (NGRC)

Preis für National Graphite Corp. (NGRC) ist $0.021

Wie hoch ist die Marktkapitalisierung für National Graphite Corp. (NGRC)

Marktkapitalisierung für National Graphite Corp. (NGRC) ist $3.24M

National Graphite Corp. (NGRC) Operative Marge

National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.

Jahr	Operative Marge	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Operative Marge

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Operative Marge	Differenz der operativen Marge	Land
Clone Algo Technologies Inc. CATI.US	0.00%	-	US
Worldwide Webb Acquisition Corp. WWAC.US	0.00%	-	US
Gushen, Inc. GSHN.US	0.00%	-	CN
Apollo Strategic Growth Capital APSG.US	0.00%	-	US
Digital World Acquisition Corp. DWAC.US	0.00%	-	US

Unternehmen

Operative Marge

Differenz der operativen Marge

Land